IVIG Portfolio Expansion
Secondary Immunodeficiency
Lifecycle ManagementExploratory/Clinical Development
Key Facts
Indication
Secondary Immunodeficiency
Phase
Lifecycle Management
Status
Exploratory/Clinical Development
Company
About ADMA Biologics
ADMA Biologics has established a unique and defensible position as the only fully integrated, U.S.-based producer of plasma-derived immunoglobulins, controlling the entire process from plasma collection to commercial manufacturing. The company's mission is to serve underserved patient populations with primary and secondary immunodeficiencies through its proprietary plasma screening and manufacturing technologies. Its strategic achievements include building a network of plasma collection centers (ADMA BioCenters), securing FDA approval for three products (ASCENIV, BIVIGAM, Nabi-HB), and achieving profitability, driven by its vertically integrated model which ensures supply reliability and favorable unit economics.
View full company profile